Back

Hepatic JNK-mediated bile acid homeostasis regulates liver cancer through PPARα

Manieri, E.; Esteban-Lafuente, L.; Rodriguez, E.; Leiva-Vega, L.; Chen, C.; Cubero, F. J.; Barrett, T.; Cavanagh-Kyros, J.; Seruggia, D.; Monte, M. J.; Marin, J. J.; Davis, R. R. J.; Mora, A.; Sabio, G.

2019-09-29 cancer biology
10.1101/783761 bioRxiv
Show abstract

cJun NH2-terminal kinase (JNK) inhibition has been suggested as a potential treatment for insulin resistance and steatosis through activation of the transcription factor PPAR. However, the long-term consequences have not been evaluated. We found that hepatic JNK deficiency alters bile acid and cholesterol metabolism, resulting in hepatic expression of FGF15 and activation of ERK in cholangiocytes, which ultimately promotes their proliferation. Genetic inactivation of PPAR identifies PPAR hyperactivation as the molecular mechanism for these deleterious effects. Our analysis indicates that hepatic PPAR activation is oncogenic: PPAR deficiency protects mice against carcinogen-induced hepatocellular carcinoma under high fat diet (HFD) condition. These surprising results urge the re-consideration of using JNK inhibitors or PPAR agonists for the treatment of metabolic syndrome.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.